The Federal Circuit ruling in Acorda v Mylan and AstraZeneca v Mylan gives branded pharmaceutical companies more flexibility in their choice of where to file suit against generics
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
National groups for the UK and the Netherlands have flagged concerns with the choice of venue, following a formal complaint from Australia’s national group